Suppr超能文献

帕金森病:运动波动

Parkinson's Disease: Motor Fluctuations.

作者信息

Factor SA

机构信息

Parkinson's Disease and Movement Disorders Center of Albany Medical Center, 215 Washington Avenue Extension, Albany, NY 12203, USA.

出版信息

Curr Treat Options Neurol. 1999 Mar;1(1):21-32. doi: 10.1007/s11940-999-0029-1.

Abstract

Motor fluctuations represent important late complications of Parkinson's disease treated with levodopa. Although treatment of these problems has improved with the emergence of numerous pharmacologic and surgical therapies, the various options can make it confusing. Pharmacologic treatment is the first step. Polytherapy is often the rule in this case with a variety of agents available as adjunctive therapy with levodopa. These adjuncts include dopamine agonists (bromocriptine, pergolide, pramipexole, ropinirole), catechol-O-methyltransferase (COMT) inhibitors (tolcapone), controlled-release formulations of levodopa, monoamine oxidase (MAO) B inhibitors (selegiline), and amantadine. The treatment can consist of any of a number of combinations of these agents. No single algorithm can be used in all patients; therapy should be individualized. Physicians treating these patients need to be well versed in late complication patterns as well as the medications chosen. In addition, optimal doses vary, and often patients are considered treatment failures and taken off medications before reaching that level. In the more complicated cases, patients should be evaluated by specialists in movement disorders. With this in mind, some guidelines are offered for the pharmacologic approach to patients with fluctuating responses to medications. For simple wearing off, controlled-release levodopa (Sinemet CR, Dupont Pharmaceuticals, Wilmington, DE), COMT inhibitors, MAO inhibitors, and dopamine agonists are reasonable options. For more complicated fluctuations, dopamine agonists with limits on levodopa are the first choice, especially when dyskinesia is present; when dyskinesia is not a factor, COMT inhibitors may be used. For dyskinesia specifically, dopamine agonists or addition of amantadine can be helpful. Surgery should be a treatment of last resort for patients in whom medical therapy fails. Patients who are candidates for medial pallidotomy should be fluctuators with severe dyskinesia and "off" periods that have not improved with pharmacologic therapy. Thalamic deep brain stimulation (DBS) should be used only in patients with tremor-predominant disease and severe intractable tremor that is unresponsive to medication and occurs not only at rest but with posture and action as well. Surgical therapy should be performed only in centers with surgeons experienced in stereotactic techniques and movement disorder specialists to ensure that the appropriate patients come to surgery and that complications are kept to a minimum. Dietary adjustment has a limited role in treating advanced Parkinson's disease.

摘要

运动波动是帕金森病左旋多巴治疗的重要晚期并发症。尽管随着众多药物和手术治疗方法的出现,这些问题的治疗有所改善,但各种选择可能会让人感到困惑。药物治疗是第一步。在这种情况下,联合治疗通常是常规做法,有多种药物可作为左旋多巴的辅助治疗。这些辅助药物包括多巴胺激动剂(溴隐亭、培高利特、普拉克索、罗匹尼罗)、儿茶酚-O-甲基转移酶(COMT)抑制剂(托卡朋)、左旋多巴控释制剂、单胺氧化酶(MAO)B抑制剂(司来吉兰)和金刚烷胺。治疗可由这些药物的多种组合中的任何一种组成。没有单一的算法可用于所有患者;治疗应个体化。治疗这些患者的医生需要精通晚期并发症模式以及所选用的药物。此外,最佳剂量各不相同,而且患者常常在达到该剂量水平之前就被认为治疗失败并停药。在更复杂的病例中,患者应由运动障碍专家进行评估。考虑到这一点,针对对药物反应波动的患者的药物治疗方法提供了一些指导原则。对于简单的疗效减退,左旋多巴控释制剂(息宁控释片,杜邦制药公司,特拉华州威尔明顿)、COMT抑制剂、MAO抑制剂和多巴胺激动剂是合理的选择。对于更复杂的波动,限制左旋多巴使用的多巴胺激动剂是首选,尤其是在存在异动症时;当异动症不是一个因素时,可使用COMT抑制剂。对于特定的异动症,多巴胺激动剂或加用金刚烷胺可能会有帮助。手术应是药物治疗失败患者的最后手段。适合内侧苍白球切开术的患者应是疗效波动且有严重异动症以及“关”期,药物治疗无效的患者。丘脑深部脑刺激(DBS)仅应用于以震颤为主的疾病且有严重难治性震颤,对药物无反应且不仅在静止时出现,在姿势和活动时也出现的患者。手术治疗应仅在有经验丰富的立体定向技术外科医生和运动障碍专家的中心进行,以确保合适的患者接受手术并将并发症降至最低。饮食调整在晚期帕金森病的治疗中作用有限。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验